Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
8.00B
Market cap8.00B
Price-Earnings ratio
26.23
Price-Earnings ratio26.23
Dividend yield
Dividend yield
Average volume
1.39M
Average volume1.39M
High today
$68.24
High today$68.24
Low today
$66.64
Low today$66.64
Open price
$67.23
Open price$67.23
Volume
987.49K
Volume987.49K
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $67.82. The company's market cap stands at 8B, with a P/E ratio of 26.23.

On 2026-04-10, Halozyme Therapeutics(HALO) stock traded between a low of $66.64 and a high of $68.24. Shares are currently priced at $67.82, which is +1.8% above the low and -0.6% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 987.49K, against a daily average of 1.39M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

HALO News

Simply Wall St 13h
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways

Halozyme Therapeutics (NasdaqGS:HALO) announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon technology....

Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways
Investing.com 3d
Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock - Investing.com

...

Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock - Investing.com
Simply Wall St 5d
How Investors May Respond To Halozyme Therapeutics Mixed Q4 Results And ENHANZE-Focused Guidance Shift

In Q4 2025, Halozyme Therapeutics reported EPS of US$0.24 and revenue of US$451.77 million, exceeding revenue expectations but falling short on earnings, while...

How Investors May Respond To Halozyme Therapeutics Mixed Q4 Results And ENHANZE-Focused Guidance Shift

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.